Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer.
The outcome of breast cancer patients with supraclavicular lymph node metastasis is generally poor, but some patients do survive for a long time. Consequently, the ability to predict the outcome is important in terms of choosing the appropriate therapy for breast cancer patients with supraclavicular lymph node metastasis. In this study, we attempted to identify functional pathways that determine the outcome of breast cancer patients with supraclavicular lymph node metastasis by profiling cDNA microarrays. Thirty-one breast cancer patients with supraclavicular lymph node metastasis without distant metastasis comprised the study cohort; these were divided into three groups based on prognosis - poor, intermediate, and good. Two functional pathways, the Wnt signaling pathway and the mitochondrial apoptosis pathway, were constructed using six genes (DVL1, VDAC2, BIRC5, Stathmin1, PARP1, and RAD21) that were differently expressed between the good and poor outcome groups. Our results indicate that these two functional pathways may play an important role in determining the outcome of breast cancer patients with supraclavicular lymph node metastasis. We also determined that immunohistostaining for the Stathmin1 gene product is a potential tool for predicting the outcome of breast cancer patients with supraclavicular lymph node metastasis.
Oishi
Yoko
Y
Department of Molecular Diagnosis, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.|Department of Vascular Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Nagasaki
Koichi
K
Genome Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Miyata
Satoshi
S
Genome Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Matsuura
Masaaki
M
Genome Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Nishimura
Sei-Ichiro
SI
Department of Breast surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Akiyama
Futoshi
F
Department Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Iwai
Takehisa
T
Department of Vascular Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Miki
Yoshio
Y
Department of Molecular Diagnosis, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. miki.mgen@mri.tmd.ac.jp.|Genome Center, Japanese Foundation for Cancer Research, Tokyo, Japan. miki.mgen@mri.tmd.ac.jp.|Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan. miki.mgen@mri.tmd.ac.jp.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology*; D016000:Cluster Analysis; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D052138:Genes, Neoplasm / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D018579:Patient Selection; D011379:Prognosis; D050777:Stathmin / Q000378:metabolism
C493995:STMN1 protein, human; D050777:Stathmin